Browsing Tag
Ruijin Hospital
3 posts
Why Novartis is paying $575m upfront for an mRNA immune-reset bet worth up to $7.8bn
Novartis has agreed to license Abogen Biosciences’ mRNA-encoded T-cell engager ABO2203 and secure options over additional RNA programs, committing $575 million upfront while leaving most of the headline $7.8 billion value contingent on future development, regulatory and commercial milestones.
CirCode Biomed’s HM2002 gets FDA green light: World’s first circular RNA drug to enter U.S. clinical trials for heart disease
CirCode’s HM2002 becomes the first circular RNA drug cleared by the FDA for clinical trials in ischemic heart disease—setting a precedent in RNA therapeutics.
AceLink Therapeutics kickstarts Phase 2 Fabry disease clinical trials in China
In a pivotal move, AceLink Therapeutics, Inc., a frontrunner in the biopharmaceutical sector, has inaugurated its first clinical…